NEW YORK (GenomeWeb News) – Foundation Medicine today announced a deal with AstraZeneca aimed at predicting a patient's response or resistance to targeted medicines.

The firms are partnering to identify genomic mutations in cancer-related tumor genes that may prove helpful to AstraZeneca in developing new therapies for patients. Foundation Medicine also was granted right of first negotiation for developing potential diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.